Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991885048> ?p ?o ?g. }
- W2991885048 startingPage "857904" @default.
- W2991885048 abstract "Anti-BRAF plus an anti-MEK is currently used in first line for the management of patients presenting metastatic melanomas harboring the BRAF V600E mutation. However, the main issue during targeted therapy is the acquisition of cellular resistance in 80% of the patients, which is associated with an increased metastasis due to the hyperactivation of MAP kinase pathway. Previous reports have indicated that Discoidin Domain Receptors (DDRs) 1 and 2 can activate this pathway. To study the role of DDRs in melanoma cell resistance to targeted therapy, we first determined that DDRs are overexpressed in vemurafenib resistant cells compared to sensitive cells. We demonstrated that DDRs depletion or inactivation by DDRs inhibitors such as dasatinib or CR-13542 reduces tumor cell proliferation, due to a decrease of MAP kinase pathway activity in resistant cells. Finally, we confirmed these results in vivo in a xenograft mouse model and show that DDRs could be new therapeutic targets in resistant patients with metastatic melanoma. We propose that dasatinib could be a second-line treatment after the bi-therapy in resistant patients overexpressing DDRs." @default.
- W2991885048 created "2019-12-13" @default.
- W2991885048 creator A5000995671 @default.
- W2991885048 creator A5008363807 @default.
- W2991885048 creator A5016826695 @default.
- W2991885048 creator A5017989408 @default.
- W2991885048 creator A5023123348 @default.
- W2991885048 creator A5024920700 @default.
- W2991885048 creator A5041653507 @default.
- W2991885048 creator A5052985728 @default.
- W2991885048 creator A5061596661 @default.
- W2991885048 creator A5062191903 @default.
- W2991885048 creator A5064711745 @default.
- W2991885048 creator A5065216530 @default.
- W2991885048 creator A5068033382 @default.
- W2991885048 creator A5076940642 @default.
- W2991885048 creator A5085057122 @default.
- W2991885048 date "2019-12-03" @default.
- W2991885048 modified "2023-10-03" @default.
- W2991885048 title "Counteracting resistance to targeted therapy in melanoma by inhibiting discoidin domain receptors" @default.
- W2991885048 cites W1790157642 @default.
- W2991885048 cites W1834835434 @default.
- W2991885048 cites W1971250281 @default.
- W2991885048 cites W1972747383 @default.
- W2991885048 cites W1986559475 @default.
- W2991885048 cites W1998470085 @default.
- W2991885048 cites W2002028874 @default.
- W2991885048 cites W2002195012 @default.
- W2991885048 cites W2002204740 @default.
- W2991885048 cites W2009459159 @default.
- W2991885048 cites W2011852093 @default.
- W2991885048 cites W2018962390 @default.
- W2991885048 cites W2028888565 @default.
- W2991885048 cites W2032211985 @default.
- W2991885048 cites W2038264590 @default.
- W2991885048 cites W2040291225 @default.
- W2991885048 cites W2046260636 @default.
- W2991885048 cites W2046409949 @default.
- W2991885048 cites W2048201531 @default.
- W2991885048 cites W2052005627 @default.
- W2991885048 cites W2052781279 @default.
- W2991885048 cites W2053679628 @default.
- W2991885048 cites W2057914157 @default.
- W2991885048 cites W2058734587 @default.
- W2991885048 cites W2060575870 @default.
- W2991885048 cites W2075240818 @default.
- W2991885048 cites W2093784914 @default.
- W2991885048 cites W2096878348 @default.
- W2991885048 cites W2100614336 @default.
- W2991885048 cites W2105435030 @default.
- W2991885048 cites W2108537717 @default.
- W2991885048 cites W2127760027 @default.
- W2991885048 cites W2128542677 @default.
- W2991885048 cites W2136368542 @default.
- W2991885048 cites W2136474966 @default.
- W2991885048 cites W2136597063 @default.
- W2991885048 cites W2144918562 @default.
- W2991885048 cites W2145449209 @default.
- W2991885048 cites W2145968308 @default.
- W2991885048 cites W2155804254 @default.
- W2991885048 cites W2160766792 @default.
- W2991885048 cites W2161400783 @default.
- W2991885048 cites W2163188200 @default.
- W2991885048 cites W2165575701 @default.
- W2991885048 cites W2166262263 @default.
- W2991885048 cites W2167961835 @default.
- W2991885048 cites W2168711434 @default.
- W2991885048 cites W2181698885 @default.
- W2991885048 cites W2184894459 @default.
- W2991885048 cites W2248712381 @default.
- W2991885048 cites W2257916031 @default.
- W2991885048 cites W2302918002 @default.
- W2991885048 cites W2304570313 @default.
- W2991885048 cites W2310968520 @default.
- W2991885048 cites W2345124923 @default.
- W2991885048 cites W2415559729 @default.
- W2991885048 cites W2473429151 @default.
- W2991885048 cites W2515845266 @default.
- W2991885048 cites W2527661220 @default.
- W2991885048 cites W2528776997 @default.
- W2991885048 cites W2564638997 @default.
- W2991885048 cites W2583338722 @default.
- W2991885048 cites W2605233023 @default.
- W2991885048 cites W2671187014 @default.
- W2991885048 cites W2737969333 @default.
- W2991885048 cites W2751614779 @default.
- W2991885048 cites W2782853604 @default.
- W2991885048 cites W2783011222 @default.
- W2991885048 cites W2787145482 @default.
- W2991885048 cites W2795353688 @default.
- W2991885048 cites W2797906965 @default.
- W2991885048 cites W2801985085 @default.
- W2991885048 cites W2802705550 @default.
- W2991885048 cites W2803614122 @default.
- W2991885048 cites W2806234074 @default.
- W2991885048 cites W2884002072 @default.
- W2991885048 cites W2889646458 @default.
- W2991885048 cites W2950011075 @default.
- W2991885048 cites W2953948952 @default.